Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus gemcitabine/cisplatin for muscle-invasive urothelial carcinoma
ChiCTR-IPC-17012721Phase 4Recruiting
- Sponsor
- Tangdu Hospital
- Start
- Sep 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of Rivoceranib in transitional cell carcinoma (TCC) and bladder cancer (2 arms), sponsored by Tangdu Hospital. Primary endpoints: progression-free survival, overall survival and 1 more. Started Sep 2017; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on ChiCTR-IPC-17012721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPC-17012721.